益气解毒方对中晚期鼻咽癌患者CD4^+CD25^+调节性T细胞和Th17细胞的影响  

Effects of Qi-Boosting Toxin-Resolving Formula on CD4^+CD25^+ Regulatory T Cells and Th17 Cells of Patients with Middle to Late Staged Nasopharyngeal Carcinoma

作　　者：江志超[1] 田道法[2] 范靖莹[2] 

机构地区：[1]湖南省第二人民医院中西医结合科,湖南长沙410007 [2]湖南中医药大学中西医结合学院,湖南长沙410007

出　　处：《中国中医药信息杂志》2014年第2期23-26,31,共5页Chinese Journal of Information on Traditional Chinese Medicine

基　　金：国家自然科学基金(30973856);湖南省中医药管理局科研重点项目(2010007)

摘　　要：目的探讨益气解毒方对中晚期鼻咽癌患者外周血CD4+CD25+调节性T细胞和Th17细胞的影响。方法用流式细胞仪检测18例经益气解毒方加常规治疗的中晚期鼻咽癌患者(观察组)及l5例常规治疗的中晚期鼻咽癌患者(对照组)外周血CD4+CD25+调节性T细胞和Th17细胞比例,RT-PCR法检测Foxp3 mRNA和ROR-γt mRNA转录水平,ELISA法检测血清白细胞介素-6(IL-6)和转化生长因子-β(TGF-β)水平。结果观察组患者外周血中CD4+CD25+调节性T细胞占CD4+T细胞的比例和Foxp3 mRNA的相对表达量均低于对照组(P<0.05),而Th17细胞占CD4+T细胞的数量比例和ROR-γt mRNA的相对表达量均高于对照组(P<0.05);观察组患者血清IL-6水平高于对照组(P<0.05),而TGF-β水平低于对照组(P<0.05)。结论益气解毒方可影响中晚期鼻咽癌CD4+CD25+调节性T细胞的比例与功能,增强Th17细胞的分化,其机制可能是通过调节IL-6和TGF-β水平而逆转鼻咽癌免疫耐受。Objective To investigate the effects of Qi-Boosting Toxin-Resolving Formula （QBTRF） on CD4＋CD25＋ regulatory T cells and Th17 cells of patients with middle to late staged nasopharyngeal carcinoma （NPC）. Methods Flow cytometry was performed to detect the ratio of CD4＋CD25＋ regulatory T ceUs and Th17 cells in the peripheral blood mononuclear ceUs （PMBC） among 18 patients with middle to late stage of NPC treated by QBTRF added to conventional therapy （treatment group）, Foxp3 mRNA and ROR-yt mRNA in PMBC was determined by RT-PCR technique. Furthermore, serum levels of IL-6 and TGF-β were assayed by ELISA. Meanwhile, 15 patients with NPC treated by conventional therapy were taken as the control group. Results The ratio of CD4＋CD25＋ regulatory T cells to the total CD4＋T cells and the transcriptional level of Foxp3 mRNA in PMBC were significantly lower in treatment group than that of control group （P 〈 0.05）, the ratio of Th 17 cells to the total CD4＋ T ceils and the transcriptional level of ROR-yt mRNA in PMBC were significantly higher in treatment group than that of control group （P〈0.05）. However, the serum level of IL-6 was obviously higher in treatment group than that of control group （P 〈0.05）, and the serum 1eve of TGF-β was obviously lower in treatment group than that of control group （P 〈 0.05）. Conclusion Q BTRF can significantly affect the number ratio and functional activity of CD4＋CD25＋ regulatory T cells and enforce the differentiation of Th17 ceils among patients with middle to late staged NPC, which it may be reversed the immune tolerance of NPC through regulating the level of IL-6 and TGF-β.

关 键 词：益气解毒方 中晚期鼻咽癌 调节性T细胞 TH17细胞 细胞因子 

分 类 号：R273.963[医药卫生—中西医结合]